Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 153,797,808
  • Shares Outstanding, K 1,594,090
  • Annual Sales, $ 25,638 M
  • Annual Income, $ 5,953 M
  • 36-Month Beta 1.51
  • Price/Sales 5.97
  • Price/Cash Flow 17.16
  • Price/Book 25.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.19 +15.52%
on 09/27/17
98.26 -2.20%
on 10/20/17
+8.69 (+9.94%)
since 09/20/17
3-Month
69.38 +38.51%
on 07/28/17
98.26 -2.20%
on 10/20/17
+22.09 (+29.85%)
since 07/20/17
52-Week
55.06 +74.54%
on 10/28/16
98.26 -2.20%
on 10/20/17
+34.34 (+55.60%)
since 10/20/16

Most Recent Stories

More News
Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics

AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.

LGND : 143.93 (+0.40%)
NVO : 50.55 (-0.26%)
ABBV : 96.10 (-0.39%)
ADAP : 7.15 (+0.70%)
Cancer Treatment Update: Second Gene Therapy Receives Approval

The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs....

AZN : 34.62 (-0.26%)
MRK : 63.88 (+0.20%)
NVS : 85.74 (-0.49%)
EXEL : 27.17 (-1.06%)
ABBV : 96.10 (-0.39%)
GILD : 81.21 (-0.47%)
INO : 6.23 (-0.32%)
BMY : 64.42 (-0.39%)
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna

AET : 160.84 (+2.03%)
ABBV : 96.10 (-0.39%)
GILD : 81.21 (-0.47%)
TEVA : 14.90 (-0.20%)
BIIB : 338.10 (-1.26%)
AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration

AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced today that they have entered...

ABBV : 96.10 (-0.39%)
What's in the Cards for Novartis (NVS) This Earnings Season?

Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.

VRTX : 154.63 (+0.02%)
NVS : 85.74 (-0.49%)
ABBV : 96.10 (-0.39%)
AMGN : 182.96 (-0.63%)
Where to Find Value in Healthcare Stocks

The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.

AET : 160.84 (+2.03%)
ABBV : 96.10 (-0.39%)
GILD : 81.21 (-0.47%)
TEVA : 14.90 (-0.20%)
BIIB : 338.10 (-1.26%)
Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

NVO : 50.55 (-0.26%)
ABBV : 96.10 (-0.39%)
REGN : 432.98 (-1.81%)
SNY : 49.51 (-1.02%)
J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

JNJ : 142.40 (+0.25%)
MRK : 63.88 (+0.20%)
ABBV : 96.10 (-0.39%)
PFE : 36.42 (+0.50%)
The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare

VMW : 118.34 (+0.80%)
ABT : 56.32 (+0.57%)
UTX : 120.93 (+1.21%)
AXP : 92.09 (+0.21%)
ABBV : 96.10 (-0.39%)
Top Research Reports for AbbVie, American Express & Abbott

Top Research Reports for AbbVie, American Express & Abbott

VMW : 118.34 (+0.80%)
ABT : 56.32 (+0.57%)
UTX : 120.93 (+1.21%)
AXP : 92.09 (+0.21%)
EMR : 65.78 (+0.95%)
ABBV : 96.10 (-0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Support & Resistance

2nd Resistance Point 99.79
1st Resistance Point 97.94
Last Price 96.10
1st Support Level 94.57
2nd Support Level 93.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart